Molecular Templates, Inc.

As of March 28, 2018, Molecular Templates, Inc. is considered risky and overvalued due to a P/E ratio of 0.00, an EV to EBITDA ratio of 0.51, a -259.19% ROE, and a year-to-date stock return of -99.75%, significantly underperforming compared to its peers and the S&P 500.

As of February 10, 2025, the market trend is mildly bearish, with daily moving averages indicating bearishness, weekly MACD showing mild bullishness, and mixed signals from KST and Dow Theory, suggesting weak bearish sentiment with potential for recovery.

As of March 2022, the management team of Molecular Templates, Inc. includes Dr. Harold Selick (Chairman), Dr. Eric Poma (CEO and CSO), and several independent directors: Dr. David Hirsch, Mr. David Hoffmann, Mr. Kevin Lalande, Mr. Jonathan Lanfear, and Mr. Scott Morenstein. This team provides governance and strategic direction for the company.

As of Jun 18, Molecular Templates, Inc. has a market capitalization of 0.00, classifying it as a Micro Cap company, with net sales of 25.48 million and a net profit of -15.63 million over the last four quarters. The company's shareholder's funds are 4.21 million, and total assets are 35.38 million as of Dec 23.